Company Name Agalimmune
Mailing Address 2875 Michelle Drive Irvine, CA 92606 USA
Company Description At Agalimmune we see harnessing and directing the protective power of the immune system as being a cornerstone of cancer therapy, now and into the future. Cancer is responsible for 13% of deaths worldwide and it is estimated that one in three of us will have cancer at some point in our lives.
Proceeds Purposes The investment will be used to fund Agalimmune’s research into combination therapy with immune checkpoint inhibitors such as the CTLA-4, PD-1, and PD-L1 classes of compounds, as part of its supportive preclinical work packages.